Shift Bioscience raised $16 million to further its AI-driven platform
Longevity Technology - 15-Oct-2024Shift aims to treat diseases like heart issues and arthritis by addressing aging’s root causes
Shift Bioscience
Simulation guided cell rejuvenation to defeat the diseases of aging
Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high throughput and high accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes the norm.
Shift Bioscience Team
- Bo Wang, Advisor
- Brendan Swain, CSO
- Lucas Camillo, Head of ML
- Daniel Ives, CEO
- David Prior, Chair
Visit website: https://shiftbioscience.com/
Details last updated 10-Sep-2020
Mentioned in this Resource
Brendan Swain
Co-founder and Chief Scientific Officer at Shift Bioscience, Inventor of the first accurate cell aging clock
David Prior
Heritage Professional and historian, Member of the House of Lords of the United Kingdom, Chair at Shift Bioscience
Shift Bioscience is also referenced in the following:
Shift Bioscience News
UK biotech races US giants for longevity breakthrough
The Guardian - 05-Nov-2023British researchers and startups vie to outpace tech billionaires in the fight against ageing
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020General feeling that failures are bound to happen - but that their approaches can succeed
